Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...
The study carried out by Dr Marta Moreno-Rodríguez in the UPV/EHU group showed that the neurotransmitter receptors in the cannabinoid family and certain choline-containing lipids in the brain ...
TGR5 agonists are attractive candidates for T2D therapy because of their ability to improve glycemic control. This study used machine learning-based models (ML), molecular docking (MD), and molecular ...